Ketamine and Bipolar Depression: What Stopped the Trials?

The Exclusion That Had Almost No Evidence Behind It

For years, ketamine for bipolar depression was ruled out by assumption, not by evidence — no controlled trial had actually tested the mania risk. That gap has now been closed, and the answer is not what the field expected.

Here is the strange part. If you walked into most ketamine clinics in North America over the past decade with a diagnosis of bipolar depression, you were shown the door. Not because a controlled trial had tested the risk and found it real. Because nobody had run that trial at all.

The underlying fear is legitimate, and worth understanding. Bipolar depression is not simply a deeper or sadder version of ordinary depression. Antidepressants, in a subset of bipolar patients, can trigger the manic switch, flipping a person from the depths of a depressive episode into a dangerous elevation of mood, sleeplessness, and impulsivity. That risk has made clinicians cautious, sometimes heroically so, when any new treatment enters the picture.

But caution and evidence are not the same thing. Ketamine — already used off-label for psychiatric conditions across the board, since it holds no FDA approval for any mood disorder indication — was simply added to the precautionary list by assumption. Screen out bipolar patients. Play it safe. The logic felt responsible.

What that logic also produced was a self-sealing gap. No trials meant no data. No data meant no access. No access meant the gap stayed sealed, year after year, while a population with some of the highest rates of treatment resistance and suicide kept waiting. The exclusion was not a finding. It was a habit dressed up as a policy.

How Ketamine Works — and Why It Works So Fast

Most antidepressants are slow renovators. They adjust the levels of serotonin or norepinephrine and then wait — sometimes six weeks — for the brain to respond. Ketamine does something structurally different.

The leading explanation involves neuroplasticity: the brain's capacity to grow new neural connections and reorganize existing ones. Ketamine appears to trigger a burst of this rewiring, particularly in circuits associated with mood regulation. Think of it less as adjusting the volume on a broken speaker and more as soldering new wiring around the damaged parts.

The speed of that effect is, by any clinical standard, remarkable. Improvements in depressive symptoms can appear within 4 to 24 hours of the first infusion. For a patient who has spent months or years cycling through failed medications, that is not just fast — it is a different category of intervention entirely.

The experience during infusion is not subtle. Dissociative symptoms — a floating sense of detachment from the body and surroundings — are a predictable part of the process. They typically peak around the 40-minute mark and resolve shortly after the drip ends. Patients are monitored throughout; these effects are manageable, but they are real, and any honest account of the treatment has to name them.

Across trials, researchers reach for the same measuring stick to quantify how much has shifted: the Montgomery-Åsberg Depression Rating Scale, or MADRS. It is a 10-item clinician rating tool that scores everything from reported sadness to concentration to suicidal thoughts. The MADRS gives different research teams a shared language, which is the only way their numbers become comparable. Without that common yardstick, the accumulating evidence would be a pile of anecdotes rather than a case.

What the Evidence Was Already Whispering

Before the 2026 Toronto trial arrived with its controlled design and its zero mania cases, the evidence had been building quietly. The Bio-K study, published in February 2024 and led by Sagar Parikh at the University of Michigan, reported a 52% remission rate in bipolar patients after just three infusions across eleven days. That number is worth pausing on. Three infusions. Eleven days. More than half of participants no longer met the clinical threshold for a depressive episode.

The signal on suicidal thinking was harder to set aside. Half of the Bio-K participants who entered the study with frequent suicidal thoughts saw a dramatic reduction in those impulses. Clinicians do not use the word "urgent" lightly, but that particular finding carries obvious weight: if a treatment can interrupt the darkest part of a depressive episode within days, the practical stakes reach well beyond symptom scores.

Then Samuel T. Wilkinson at Yale School of Medicine asked a different question. Instead of looking at a trial population, he looked at real patients in real clinics — the kind of people who do not always fit the tidy inclusion criteria of a controlled study. His retrospective review found a 39% clinical response rate. That matters because trial results sometimes live only in the greenhouse of optimal conditions, and 39% in the wild is a meaningful echo of what the trials were showing.

The picture was compelling. The gap was just as clear: none of these studies could silence the mania-risk argument the way a rigorous, controlled trial could. That study was still coming.

The Ket-BD Trial: Sixty-Eight People, Four Infusions, One Number That Mattered

Picture a clinic room in Ontario on an unremarkable Tuesday morning. A patient with treatment-resistant bipolar depression settles into a chair, and a slow drip begins — either ketamine or midazolam, a sedative calm enough to feel like something without being anything at all. Neither the patient nor the clinician knows which. That deliberate blindness is the point.

The Ket-BD study ran at three sites across Ontario, designed as a double-blind, midazolam-controlled randomized clinical trial — the most rigorous architecture the field had yet aimed at this specific population. Sixty-eight adults with bipolar I or II depression, all treatment-resistant, received four intravenous infusions over two weeks. The doses ran between 0.5 and 0.75 mg/kg, the same range used in unipolar work, the same slow drip across the same forty-odd minutes.

The response numbers came out clearly in favor of ketamine: 35.3% of the ketamine group responded, against 11.8% in the control group. Remission — full remission, not just improvement — reached 17.6% for ketamine versus 8.8% for midazolam. Those are meaningful gaps for a population that has often exhausted every other option on the formulary.

But the number the whole trial was quietly organized around was not a percentage at all. It was zero. Zero participants experienced a manic episode. Zero cases of psychosis. The manic switch — the specter that had kept bipolar patients out of ketamine clinics for years — did not appear. Not once, across sixty-eight people, four infusions each.

A single trial is not a verdict. The researchers knew that; so did the editors at JAMA Psychiatry who published the results in September 2026.

The manic switch — the specter that had kept bipolar patients out of ketamine clinics for years — did not appear. Not once, across sixty-eight people, four infusions each.

What Zero Actually Means for Bipolar Depression Treatment

One zero does not close a debate. Anyone who has spent time around clinical research knows that a single trial, however well designed, is a data point, not a verdict. But zero mania events in 68 bipolar patients during controlled ketamine infusions is not an ordinary zero. It is the kind of number that forces a field to revise what it thought it knew — the way a single counterexample collapses a confident generalization.

Compare this to the history of antidepressants in bipolar care, where the mania risk was so routinely observed that it became standard practice to screen bipolar patients out of entire treatment categories. That caution was earned the hard way. Ketamine's zero is meaningful precisely because it arrived in the same controlled conditions where other drugs had failed the same test.

The field has not waited for perfect certainty to act. Clinical guidelines already recommend ketamine as an adjunctive therapy, used alongside mood stabilizers like lithium rather than instead of them. The logic is sound: keep the mood floor stable with a known agent, then let ketamine work on the depression above it.

In August 2026, the American Society of Ketamine Physicians, Psychotherapists, and Practitioners published updated evidence-based standards — a signal that the conversation has moved from "should we?" to "how, exactly."

The Horizon Still Open: What We Do Not Yet Know

A trial of 68 people over two weeks answers one question cleanly and opens four others. That is not a criticism. That is how science works.

The most pressing gap is time. The Ket-BD trial tracked participants through an induction phase, not through a year or five years of life with this treatment. What serial infusions do to the brain across months of maintenance dosing, nobody yet knows with controlled evidence. The optimal frequency of those maintenance infusions, after the initial two-week burst, remains an open number.

There is also a population question with real stakes. Every trial reported here enrolled patients who were already taking mood stabilizers like lithium. Whether ketamine is safe for bipolar patients who are not on a stabilizer is entirely untested. The clinical guidelines assume the answer is "probably not," but assumption is not data.

A third gap sits in the pharmacy. Spravato — the FDA-approved esketamine nasal spray for unipolar depression — is already used off-label in bipolar patients. Nobody has yet run a rigorous head-to-head comparison between the nasal spray and intravenous ketamine specifically in the bipolar subtype. NRx Pharmaceuticals is targeting 2027 for a New Drug Application for NRX-100, a preservative-free intravenous formulation, so the regulatory machinery is at least in motion.

What the 2026 trial gave us is a door, not a room. A fear that kept an entire population away from a promising treatment for bipolar depression has been tested and, so far, not confirmed. The next question is whether that holds across a lifetime of treatment — and for now, that notebook entry remains stubbornly blank.